title: Comments about the editorial by Bénédicte Mugnier and Jean Roudier entitled "Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally".
authors.forename: Thierry
authors.initials: T
authors.lastname: Lequerré
authors.forename: Olivier
authors.initials: O
authors.lastname: Vittecoq
authors.forename: Xavier
authors.initials: X
authors.lastname: Le Loët
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D015870:Gene Expression; D005819:Genetic Markers; D006801:Humans; D000069285:Infliximab; D011110:Polymorphism, Genetic; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005819:Genetic Markers; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab